KOP's Center for Breakthrough Medicines sells controlling interest to South Korean firm

The South Korean conglomerate invested $350 million in King of Prussia's Center for Breakthrough Medicines in December 2021.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 20, 2023 Category: Pharmaceuticals Authors: John George Source Type: news